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ABSTRACT 
The blood-brain barrier (BBB) is a specialized system that comprises brain microvasculature 
endothelial cells, basement membrane and various types of cells, including astrocytes, pericytes 
and neurons located close to the endothelium. The BBB is a key element for the central nervous 
system (CNS), as it shields the brain from toxic substances in the blood, supplies brain tissues with 
nutrients and filters harmful compounds from the brain back to the bloodstream. Understanding 
of its complex structure is essential to make a step further in the discovery of new effective brain 
treatments. Actually, gene therapy is bringing about new horizons in the treatment of brain 
disorders, however, it has to solve the transport across the BBB of its large therapeutic molecules. 
Compared to other gene therapy techniques, such as viral gene delivery or cationic liposome 
delivery, the Trojan horse liposome technique seems to have some advantages. Trojan horse 
liposomes, together with avidin-biotin and fusion protein technologies, are three different 
techniques that researchers are studying to carry drugs into the brain via a receptor-mediated 
transcytosis. During the last few years a lot of studies in animal models in vitro and in vivo have 
emerged, but research has not yet reached clinical trials.  
 
RESUM 
La barrera hematoencefàlica és un sistema especialitzat que està format per cèl·lules endotelials, 
membrana basal i diversos tipus de cèl·lules com astròcits, pericits i neurones localitzats a prop de 
l’endoteli. La barrera hematoencefàlica és un element clau per al sistema nerviós central, ja que 
protegeix el cervell de substàncies toxiques provinents de la sang, proveeix el teixit cerebral de 
nutrients i filtra compostos nocius del cervell cap a la circulació sanguínia. La seva estructura és 
complexa, però el seu coneixement és essencial per al descobriment de nous tractaments 
cerebrals més efectius. Actualment, la teràpia gènica està obrint nous horitzons pel que fa al 
tractament de malalties del sistema nerviós, tot i així, encara ha de resoldre el problema de com 
fer que les seves molècules terapèutiques grans travessin la barrera hematoencefàlica. La tècnica 
que utiliza liposomes com a cavalls de Troya moleculars sembla presentar alguns avantatges 
respecte d’altres tècniques, com el transport a través de virus o de liposomes catiònics.  Aquesta 
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tecnologia, junt amb les de l’avidina-biotina i de la proteïna de fusió, són tres tècniques differents 
que els investigadors estan estudiant per al transport de fàrmacs a través de la barrera via 
transcitosi mitjançada per receptors. Durant els últims anys s’han fet molts estudis en models 
animals in vitro i in vivo, però encara no s’ha aconseguit arribar als assaigs clínics. 
 
INTEGRATION OF THREE DIFFERENT SCOPES 
This assignment is framed in the Physiology and Physiopathology scope, and also in the 
Pharmacology and Therapeutics and Cellular Biology scopes.  
 
• Physiology and Physiopathology: this work describes the physiological functioning of the 
BBB which is essential for the homeostasis of the central nervous system. Given that the 
BBB impedes the pass to the brain of therapeutic substances or substances used for 
diagnosis to the brain, different transport mechanisms and strategies directed to cross the 
BBB are studied. 
• Pharmacology and Therapeutics: this work studies different drug delivery techniques that 
can be used to cross the BBB. Besides, it gives special attention to gene therapy and the 
Trojan horse liposome technique. 
• Cellular biology: this work describes different types of transport across the BBB and 
focuses on receptor-mediated transcytosis. This implies processes of cellular 
internalization. Besides, the detailed description of the structure of the BBB is based on 
physiology as well as cellular biology. 
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1. INTRODUCTION 
 
1.1 THE BLOOD-BRAIN BARRIER 
The blood-brain barrier (BBB) is a complex structure essential to maintain the central nervous 
system (CNS) homeostasis. This barrier is necessary to prevent certain hazardous substances from 
entering to the central nervous system and to facilitate the entrance of nutrients and chemical 
signals. 
The BBB is formed by the microvasculature of the brain and its particular properties are given by 
the expression of BBB-specific genes (1). There are different cells that comprise the brain 
microvasculature, and all contribute to its regulation including permeability. Within the 
microvasculature there are endothelial cells and pericytes which share a common capillary 
basement membrane. There is approximately one pericyte for every two to four endothelial cells. 
Furthermore, more than 99% of the brain surface or abluminal surface of the capillaries is covered 
by astrocytic foot processes. The capillaries are also innervated by nerve endings of either intra- or 
extra-cerebral origin. The distance between the astrocyte foot process and the capillary 
endothelial cell and the pericyte is only 20 nm. Therefore, the interrelationships between them 
are as intimate as any cell-cell interactions in biology. The space filled by the basement membrane 
and situated between the endothelium/pericyte and the astrocyte foot process forms the 
interface between blood and brain (2). 
Brain capillaries are much less permeable than capillaries in most other tissues so that even small 
molecules cannot pass the capillary walls. This is caused mainly from very extensive tight junctions 
between the endothelial cells. Compared to capillary walls of other organs, which present less 
tight junctions and so let water flow, brain capillaries prevent water-soluble substances from 
passing through them (3). 
However, certain areas of the brain, most of which are situated close to the ventricle and are 
therefore called circumventricular organs (CVO), have endothelial cells that do not form tight 
junctions. These areas together comprise less than 1% of the brain, and the endothelium is 
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fenestrated with circular pores which allow free exchange of molecules between the blood and 
the adjacent neurons. The epithelial cells, which delimit the circumventricular organs, however, 
impede diffusion into the rest of the brain and the cerebrospinal fluid (CSF). Therefore, substances 
that have entered these areas do not have unrestricted access to the rest of the brain (2). 
Other particular characteristics of the BBB are the lack of lymphatic drainage and the absence of 
major histocompatibility complex (MHC) antigens. The BBB has strict limit for the passage of 
immune cells, especially lymphocytes, and its immunity is constituted by the association between 
BBB endothelial cells, perivascular macrophages and mast cells. Additionally, the BBB immunity is 
reinforced by local microglia cells (4). 
 
1.2 PERMEABILITY AND TRANSPORT ACROSS THE BBB 
The brain is protected against peripheral neurotransmitters, cytotoxins or microorganisms 
because passive diffusion is only possible for small molecules (less than 400-500 Da) which are 
highly lipid soluble. This property, which is a protection, is a disadvantage for hydrophilic 
molecules and hence hydrophilic drugs (1). As an example, certain drugs such as barbiturates are 
highly lipid-soluble and act rapidly, and other drugs, such as penicillin, have low lipid solubility and 
pass the BBB with difficulty. The need for such a barrier is due to the delicate balance of neuronal 
excitability that must be kept out of disturbing agents (3). 
But not all molecules which are necessary for the CNS can passively diffuse through the BBB, and 
thus the only way to gain access to the brain is through specific transporters located on both 
luminal and abluminal membranes of the BBB. Glucose, amino acids or insulin are examples of 
molecules that use this type of transport. Glucose is an example of a water-soluble substance that 
reaches high concentrations in the brain. This is essential as the neurons depend, almost only, on 
glucose as a source of energy. The glucose transporter GLUT 1 is specific to brain capillaries (3). 
Macromolecules, such as some growth factors and cytokines, are to a limited extend carried from 
blood plasma to the brain, by receptor-mediated transport. Insulin or transferrin are also 
transferred across the barrier via this type of transport (3). 
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The BBB is able to actively pump ions that are present in different concentration in the brain 
extracellular fluid and in the blood plasma such as Na+, K+ or Ca2+. Organic acids are as well actively 
pumped out of the brain by specific transporters (3). 
Transport of small and large molecules through the BBB is restricted and, moreover, the BBB is 
equipped with efflux transporters that actively expel substances out of the brain. One of the most 
characterized efflux transport is P-glycoprotein, and it is responsible for the transports of many 
drugs out of the brain (3). 
Among the different types of transport present in the BBB, the receptor-mediated transcytosis has 
been chosen to illustrate how new treatment strategies use endogenous mechanisms to 
overcome the difficulty to access into the brain. Various techniques can be used to deliver drugs 
through receptor-mediated transcytosis, however this work will focus on one of these techniques 
to have a more detailed understanding of its engineering and how gene therapy can beneficiate of 
its advantages compared to other existing gene therapies. 
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2. OBJECTIVES 
 
This work pretends to review the actual research about BBB structure and drug delivery across the 
barrier. The specific objectives are the following: 
 
-To describe the structure of the BBB and how it confers its particular characteristics. 
-To explain ways of transport across the BBB and go through the various types of transport 
mechanisms and the different types of transporters. 
-To explain in a detailed manner the receptor-mediated transcytosis, its main receptors and 
include a detailed description of the molecular Trojan horses.  
-To describe different drug delivery techniques that use receptor-mediated transcytosis.  
-To give a brief account of the importance of gene therapy in the future of effective brain 
treatments and the different strategies that have been used to date.  
-To describe thoroughly the Trojan horse liposome gene delivery technique, referring to its actual 
engineering.  
-To give general aspects of the research and future perspectives of the Trojan horse liposomes as 
well as those of other techniques. 
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3. MATERIAL AND METHODS 
 
This assignment is a bibliographic research. The sources belong to cientific articles collected in 
Pubmed and books specialized in the central nervous system and drug delivery to the brain.  
The first search in Pubmed was based in the key words “blood-brain barrier” AND “antibody” AND 
“trojan horse”. From the results obtained, a recent review was chosen. Some of the bibliography 
of this review was used to obtain more information. Besides, other searches were done with key 
words such as “Trojan horse liposomes” or “gene therapy” or “receptor-mediated transcytosis”. 
Among the articles used, some are reviews and others research papers. 
A lot of articles date from 2007 onwards to have recent and actualized information, but some 
anterior interesting bibliography has also been used.    
To complement the search, various useful books were found using the library catalog. The first 
search was with the key word “blood-brain barrier” and the following searches used, as key words, 
“central nervous system” and “Trojan horse”. Some books were available online and others were 
found in the libraries of the Faculty of Pharmacy and the Faculty of Medicine. 
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4. RESULTS 
 
4.1 STRUCTURE OF THE BLOOD-BRAIN BARRIER 
 
The BBB is comprised of endothelial cells of brain microvasculature 
and also other types of cells as shown in figure 1. These cells will be 
explained in the present chapter. 
 
Figure 1. Schematic outline of the capillary of the BBB in a 
transverse section showing its different components. (5) 
 
4.1.1 Endothelial cells 
Brain capillaries are continuous and their walls are composed of one or more endothelial cells. The 
main features that distinguish endothelial cells from those that do not belong to brain vessels 
form the structural basis of the BBB. These include the presence of tight junctions between 
cerebral endothelial cells, reduced endothelial plasmalemmal vesicles or caveolae, albondin, 
glycocalyx and increased numbers of mitochondria (2).  
Within the endothelial cells of brain capillaries there are enzymes which inactivate some 
substrates. These enzymes are located not only within the endothelial cells, but also in brain tissue 
generally (6). Enzymatic activity is carried by enzymes such as alkaline phosphatase (ALPase), acid 
phosphatase (ACPase), 5’-nucleotidase (5’-N), adenosine triphosphatase-Na+, k+-ATPase, 
nucleoside diphosphatase (NDPase) (5). 
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4.1.1.1 Junctional complex 
The most differential characteristic of these 
endothelial cells is tight junctions. These junctions 
are characterized by fusion of the outer leaflets of 
adjacent plasma membranes at intervals producing 
a pentalaminar appearance and forming tight or 
occluding junctions that prevent paracellular 
diffusion. These tight junctions form the most apical 
element of the junctional complex, which includes 
both tight and adherens junctions. Tight junctions 
extend circumferentially around cerebral 
endothelial cells; hence, their name zonula occludens (2,5). Figure 2 shows the junctional complex 
and the major proteins associated to tight and adherens junctions. 
The physiologic correlate of tightness in epithelial membranes is electrical resistance. It is 
estimated to be approximately 4000-8000 Ω/cm2 compared to leaky epithelia which generally 
exhibits electrical resistances between 100-200 Ω/cm2 (2).  
Tight junctions are composed of an intricate combination of trans-membrane and cytoplasmic 
proteins linked to an actin-based cytoskeleton that allows these junctions to form a seal while 
remaining capable of rapid modulation and regulation (2). Three integral proteins –claudin 1 and 
2, occluding and junction adhesion molecule (JAM)- form the tight junction (2). Claudins form 
dimmers and bind homotypically to claudins on adjacent endothelial cells to form the primary seal 
of the tight junction. In the other hand, occludin is a regulatory protein, whose presence at the 
BBB is correlated with increased electrical resistance across the barrier and decreased paracellular 
permeability. Besides, occludin is not present in non-neural vessels thus differentiating the tight 
junctions of cerebral and non-neuronal vessels (2).  The third type of integral proteins that are 
localized at the tight junctions are junctional adhesion molecules (JAM) which are members of the 
immunoglobulin superfamily, and can function in association with platelet endothelial cellular 
adhesion molecule 1 (PECAM) to regulate leukocyte migration. Overexpression of JAM in cells that 
do not normally form tight junctions increases their resistance to the diffusion of soluble tracers, 
suggesting that JAM contributes to permeability control (2).  
Figura 2. Major proteins associated with the junctional complex at 
the BBB. (2) 
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Tight junctions are also made up of several accessory proteins that are necessary for structural 
support such as ZO-1 to 3, AF-6, 7H6 and cingulin. The zonula occludens (ZO) proteins 1-3 belong 
to a family of proteins involved in the coupling of transmembrane proteins to the cytoskeleton. 
The ALL-1 fusion partner from chromosome 6 (AF-6) is associated with ZO-1 and serves as a 
scaffolding component of tight junctional complexes by participating in regulation of cell-cell 
contacts via interaction with ZO-1. 7H6 antigen is a phosphoprotein found at tight junctions that is 
impermeable to ions and macromolecules. Lastly, the double-stranded myosin-like protein 
cingulin is localized at the tight junction and found in endothelial cells as well and it appears to 
serve as a scaffolding protein that links tight junction accessory proteins to the cytoskeleton (2). 
The primary cytoskeleton protein, actin, has known binding sites on all ZO proteins and on claudin 
and occludin. Tight junctions are localized at cholesterol-enriched regions along the plasma 
membrane associated with caveolin-1. Caveolin-1 interacts with and regulates the activity of 
several signal transduction pathways and downstream targets. Furthermore, several cytoplasmic 
signaling molecules are concentrated at tight junction complexes and are involved in signaling 
cascades that control assembly and disassembly of tight junctions (2). 
Adherens junctions are located near the basolateral side of endothelial cells. Adherens junction 
proteins include different types of catherins, which are single-pass transmembrane glycoproteins 
that interact homotypically in the presence of Ca2+. These catherins are not specific for cerebral 
endothelial junctions being present in endothelium of non-neural blood vessels as well. Cadherins 
are linked intracellularly to a group of proteins termed catenins. Catenins are part of the system by 
which adherens and tight junctions communicate (2). 
 
4.1.1.2 Plasmalemmal vesicles or caveolae 
Within endothelial cells there are endothelial plasmalemmal vesicles or caveolae. These are non-
coated structures also referred to as pinocytotic vesicles. Free cytoplasmic caveolae are spherical 
structures. The decreased number of vesicles in cerebral endothelium implies limited transcellular 
traffic of molecules. Endothelial caveolae are either endocytic or transcytotic. The permeant 
molecules can either be internalized within endothelial cells by endocytosis or may be 
translocated across the cell to the interstitial fluid, a process termed transcytosis. Both 
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endocytosis and transcytosis may be receptor-mediated or fluid phase and require ATP. Receptor-
mediated transcytosis of caveoli are involved in transport of low density lipoprotein (LDL), β-very 
low density lipoprotein (VLDL), transferrin, insulin, albumin, ceruloplasmin, and transcobalamin 
across the endothelium (2). 
 
4.1.1.3 Albondin 
Albondin is a 60-kDa albumin-binding sialoglycoprotein that is expressed selectively by vascular 
endothelium and is present on the luminal surface of continuous endothelium. It binds albumin 
apparently not only to initiate its transcytosis via caveolae but also to increase capillary 
permselectivity. Low expression or lack of expression of albondin in brain-derived microvascular 
endothelial cells accounts for restricted albumin passage into brain (2). 
 
4.1.1.4 Mitochondria 
Most of the mitochondria in cerebral endothelium are located in the vicinity of the nucleus, but 
occasional mitochondria occur throughout the cytoplasm and these tend to be parallel to the cell 
surface. Increased mitochondria in cerebral endothelium may provide the metabolic work capacity 
for maintaining the ionic gradient across the BBB (2). 
 
4.1.1.5 Glycocalyx 
The glycocalyx is a negatively charged, surface coat of proteoglycans and adsorbed plasma 
proteins lining the luminal surface of the endothelium. Therefore it works at the first line of the 
BBB. It is thought that it contributes to the vasculoprotective effects of the vessel wall and that is 
involved in maintaining vascular permeability. Glycocalyx harbours a wide array of enzymes that 
might contribute to its vasculoprotective effect. The glycocalyx damage shifts the balance towards 
a pro-oxidant state. These observations are of particular interest because altered vascular 
permeability attenuated the earliest characteristics of atherogenesis.  Moreover, it is known that 
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endothelial glycocalyx is disturbed in various types of vascular diseases and that inflammation 
induces glycocalyx shedding (5).  
 
4.1.2 Pericytes 
In the CNS, pericytes have an oval to oblong cell body arranged to the vessel long axis. The cell 
body of the pericyte consists of a prominent nucleus with limited perinuclear cytoplasm from 
which extend cytoplasmic processes that also run parallel to the long axis of the blood vessel; 
secondary processes arise along the length of the primary process and partially encircle the 
vascular wall. Pericytes may be “granular” or “agranular” depending on whether cytoplasmic 
lysosomes are abundant or sparse respectively. The cerebral pericytes are exclusively granular and 
are rich in cytoplasmic plasmalemmal vesicles. Although pericytes are separated from 
endothelium by the basement membrane, there are gap-junctions between them. Cytoplasmic 
processes of the pericyte indent the endothelial cell and vice versa, forming the so-called “peg-
and-socket” contacts. Three major functional roles have been ascribed to pericytes associated 
with CNS microvasculature. They include contractility, regulation of endothelial cell activity and a 
role in inflammation (2). 
 
4.1.3 Basement membrane 
The basement membrane is a specialized, extracellular matrix, which separates endothelial cells 
and pericytes from the surrounding extracellular space. In adults this membrane is 30-40 nm thick 
and is synthesized by both astrocytes and endothelial cells which are connected with the 
basement membrane via fine filaments. The basement membrane has an inner electron-dense 
layer called the lamina densa; and less electron-dense layers called the laminae rarae. The 
basement membrane is composed of laminin, collagen IV, proteoglycans, notably heparan 
sulphate, fibronectins, nidogen and entactin. The chemical composition of these individual 
basement membrane components differ among various organs. The subendothelial basal lamina is 
no impediment to the extracellular flow of tracers such as horseradish peroxidase. The basal 
lamina of capillaries forms a negatively charged screen or filter controlling the movement of 
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charged solutes between blood and the brain interstitial fluid. Large, charged molecules such as 
ferritin do not cross the basal lamina. The subendothelial basal lamina also serves as a repository 
for growth factors such as basic fibroblast growth factor and heparin binding proteases and 
protease inhibitors. Therefore regulated release of growth factors and proteases from the basal 
lamina reservoir could play a role in angiogenesis and the invasion of the interstitium by tumor 
cells (2). 
 
4.1.4 Astrocytes 
Astrocytes are one of the three types of glial cells. Glial cells do 
not take part in the fast and precise information processing in 
the brain, nevertheless are of crucial importance to proper 
functioning of neurons. In fact, the number of glial cells is much 
higher than the number of neurons. The name glia derives 
from the older notion that glial cells served as a kind of glue, 
keeping the neurons together. Astrocytes have numerous 
processes that contact capillaries and the lining of the cerebral 
ventricles. They serve important homeostatic functions by 
controlling the concentrations of ions and the osmotic pressure 
of the extracellular fluid (water balance), thereby helping to keep the neuronal environment 
optimal. Astrocytes also take part in repair processes and have structural features that make them 
well suited to control the extracellular environment of the neurons (3).  
First of all, they have numerous short or long processes that extend in all directions, as shown in 
figure 3. Thus, astrocytes have a very large surface area that enables efficient exchange of ions and 
molecules with the extracellular fluid (ECF). Furthermore, some processes contact the surface of 
capillaries with expanded end-feet and cover 99% of the brain surface of the capillary basement 
membrane. Some other processes form a continuous, thin sheet (membrana limitans or glia 
limitans) where nervous tissue borders the cerebrospinal fluid (CSF), that is, in the cavities inside 
the CNS and against the connective tissue membranes on its exterior. And finally some processes 
 
Figura 3. Relationship between astroglia and 
neurons, blood vessels and the cerebrospinal 
fluid (CSF). (3) 
 
14 
 
contact neuronal surfaces as well; in this manner, parts not contacted by neurons are covered by 
glia (3).  
Astrocytes are coupled by numerous gap junctions (nexus), allowing free passage of ions and other 
small particles among them. Thus, apart from allowing electric currents to spread, astrocytes form 
continuous, large fluid volumes for distribution of substances removed from the ECF (3). 
Although glial cells do not send precise signals over long distances, they can produce brief electric 
impulses (currents) by opening of membrane channels for Ca2+. Such an opening can be evoked by 
binding of neurotransmitters to receptors in the glial cell membrane. Thus, neuronal activity can 
directly influence the astrocytes, whereas the latter affects neuronal activity. Owing to the electric 
coupling (nexus) of the astrocytes, the “calcium signal” can presumably spread rapidly in networks 
of astroglial cells, and consequently influence many neurons almost simultaneously, which, among 
other roles, can help synchronize the activity of neurons in a group. When activated, the 
astrocytes increase local blood flow (3). 
The intimate contact with neurons, capillaries, and the CSF places astroglial cells in a unique 
position to control the environment of the neurons, that is, the extracellular (interstitial) fluid of 
the brain. Such control is vitally important for three main reasons. First, neurons are exquisitely 
sensitive to changes in extracellular concentrations of ions and neurotransmitters. Second, the 
osmotic pressure (the water concentration) must be tightly controlled because the brain cannot 
expand in the skull. Third, adding even minute amounts of a substance may produce a substantial 
increase in its extracellular space in the brain. Besides, the tortuous shape of the extracellular 
space hampers free diffusion of particles (3). 
With regards to extracellular ions, the control of K+ is particularly important. Neuronal excitability 
is strongly influenced by small changes in the amount of K+. Astrocytes help remove K+ to prevent 
high toxic concentrations of this ion. Furthermore, astrocytes contribute to extracellular pH 
control by removing CO2 (3). Also, extracellular neurotransmitter concentrations must be tightly 
controlled, because proper synaptic functioning requires that their extracellular concentrations be 
very low, except during the brief moments of synaptic release. Astrocytes help to remove them 
from the synapses (3).  
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Astrocytes are also involved in the control of the extracellular osmotic pressure, that is, in 
controlling the water balance of the brain. Of particular interest in this respect are channels for 
transport of water –aquaporins- that are present in the membranes of astrocytes. Aquaporins in 
the brain are most abundant on the glial processes that are in close contact with capillaries and 
the CSF. Exchange by astroglial cells of small neutral molecules, such as the amino acid taurine, 
may be another mechanism to control extracellular osmolarity. Finally, the layer of astrocytic 
processes surrounding brain capillaries helps to prevent many potentially harmful substances from 
entering the brain (3). 
 
4.2 TRANSPORT ACROSS THE BBB 
Transport of substances in either direction of brain to 
blood, or blood to brain, requires movement across the 
capillary endothelial plasma membranes. The luminal and 
abluminal membranes of the capillary endothelium are 
separated by 100-300 nm of endothelial cytoplasm. 
Therefore, solute transfer across the capillary endothelial 
barrier is a process of transport through two membranes 
in series. However, in order for a molecule to move from 
blood to the brain interstitial space beyond the astrocyte 
foot process, the molecule must also escape the 
immediate perivascular space bordered by the plasma membranes of the capillary endothelial cell, 
pericyte, and astrocytic foot processes. Many “enzymatic BBB” mechanisms may operate within 
this space. The actual transport of nutrients or drugs across the BBB may be the result of a 
complex interplay between active efflux systems located on the endothelial plasma membrane, 
active transporters within the astrocytic foot process, and ectoenzymes present on the pericyte 
plasma membrane (2), as shown in figure 4.  
The bottleneck in the development of new drugs for the brain is the permeability of BBB. 
Unfortunately, only small molecules which are both lipid soluble and have a molecular weight 
<400 Da (8), and are not bound by plasma proteins or are not a substrate of an efflux transport, 
Figura 4. Intimate relationship of active efflux systems 
within the brain capillary endothelial membrane, 
ectoenzymes in the pericyte, and p-glycoprotein (Pgp) 
in the plasma membrane of astrocyte foot processes 
(7)  
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can cross the BBB by passive diffusion in pharmacologically significant amounts (9). In this case, 
substances dissolve in the cell membrane and cross the barrier, e.g. alcohol, nicotine, and caffeine. 
Actually less than 5% of all drugs are effective in the brain (8). In the absence of the lipid-mediated 
pathway, circulating molecules may gain access to brain only via transport on certain endogenous 
transport systems within the brain capillary endothelium (9). Products of biotechnology such as 
recombinant growth factors and enzymes, monoclonal antibodies (MAb), antisense RNA drugs, 
short interfering RNA (siRNA), or gene therapy are large molecules which need a type of transport 
to get through the BBB (8). 
 
4.2.1 Transport mechanisms at the BBB 
There are various transport mechanisms at the BBB, as shown in figure 5. Drugs may use these to 
cross the barrier. As explained above, the paracellular aqueous and the transcellular lipophilic 
pathways are difficult as a result of the tight junctions and the size of lipid-soluble molecules, 
respectively (6).   
The rest of the molecules need other types of transport across the barrier. Proteins such as 
glucose, amino acids or purines are transported via a carrier-mediated transport through the BBB 
(6). Carrier-mediated transport involves the binding of a solute to a protein transporter on one 
side of the membrane that triggers a conformational change in the protein, resulting in the 
transport of the substance to the other side of the membrane, from high to low concentration. If 
compounds need to be moved against a concentration gradient, ATP may provide the energy to 
facilitate the process (4).  
In addition, various nonselective transporters are responsible for the active transport of 
endogenous and xenobiotic compounds. Pgp is one of the best characterized transporters, but 
other transporters, such as multidrug resistance proteins (MRP) or other cation or anion 
transporters, are present as well. These nonselective transporters are mainly responsible for the 
limited uptake of several drugs in the brain. Carrier-mediated transport and active efflux transport 
will be explained in the next chapter (6). Furthermore, specific receptor-mediated transcytosis can 
transport molecules such as insulin or transferrin (6), and this process will be described in more 
detail in chapter 4.3.  
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On the other hand, adsorptive transcytosis is a vesicular transport triggered by an electrostatic 
interaction between a positive charged substance, usually the charged moiety of a peptide, and a 
negatively charged plasma membrane surface (4) that can carry lectins or cationic proteins across 
the BBB (6). In the case of some lectins (glycoproteins), the transport across the BBB is mediated 
by wheat germ agglutinin (WGA). Lectin-bound WGA causes depletion of membrane proteins, 
which in turn leads to lipid transitions and results in a significant alteration in membrane fluidity 
and permeability. These membrane modifications make possible its transcytosis. On the other 
hand, cationic proteins have a net positive charge that binds the anionic sites on the brain capillary 
endothelium, and this binding triggers the absorptive-mediated endocytosis and transcytosis. Even 
though, there are proteins that are naturally cationic, like protamine and histone; some proteins 
can be cationizated to enhance their cellular uptake by adsorptive-mediated transcytosis, like the 
cationized human serum albumin (HSA) or cationized monoclonal antibodies (MAbs) (7).   
Last, cell-mediated transcytosis is a more recently identified route of drug transport across the 
BBB, although it is a well established mechanism for some pathogens such as HIV entry into the 
brain. This transport relies on immune cells such as monocytes or macrophages to cross the intact 
BBB. Unlike other transports, cell-mediated transcytosis is unique in that it can be used virtually 
for any type of molecules or materials (4).  
 
 
Figure 5. Various transport mechanisms of drugs through the BBB (4) 
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4.3 TYPES OF TRANSPORTERS AT THE BBB AND DRUG STRATEGIES 
There are three broad classes of transporters within the BBB. 
4.3.1 Carrier-mediated transporters (CMT) for small molecules 
The CMT include the GLUT1 glucose transporter, the LAT1 large neural amino acid transporter, the 
CAT1 cationic amino acid transporter, the MCT1 monocarboxylic acid transporter, and many other 
transporters that mediate either the influx of nutrients, hormones, or vitamins from blood into 
brain, or the bi-directional movement of these molecules between the blood and brain 
compartments. The CMT system may be expressed at both luminal and abluminal membrane. In 
the latter situation, another CMT system must function at the abluminal membrane, so as to 
mediate the transport of the solute across both membranes (10). 
 
4.3.2 Active efflux transporters (AET) for small molecules 
The AET include P-glycoprotein and other members of the ATP-binding cassette (ABC) gene family. 
However, there are several MRP transporters, which also belong to ABC gene family. The energy-
dependent ABC transporters at the BBB work in concert with an energy-independent transporter, 
generally a member of the Solute Carrier (SLC) gene family, to mediate the active efflux of 
metabolites and drugs from brain to blood. ABC transporter is expressed at one of the two 
endothelial membranes, while an SLC transporter is expressed at the opposite membrane (10). 
Figure 6 shows an example of an active efflux transport. 
 
Figure 6. Example of an active efflux transport, it shows the members 
of the ABC gene family at the luminal endothelial membrane, and the 
members of the SLC gene family at the abluminal endothelial 
membrane, although it could be the opposite (9). 
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4.3.3 Receptor-mediated transporters (RMT) for large molecules 
The RMT include receptors such as the IR, transferrin receptor (TfR) (10), leptin receptor (OBR) (2), 
Fc receptor (FcR), type 1 scavenger receptor (SR) and insulin-like growth factor receptors 1 and 2 
(10). 
This pathway involves several sequential steps. First, there is binding of the circulating peptide or 
peptidomimetic MAb to an specific receptor on the luminal membrane and this is followed by 
endocytosis of the receptor-ligand complex. Following entry into the preendosomal compartment 
immediately distal to the plasma membrane, the peptide is triaged into one of the following RMT 
systems (7) shown in figure 7. 
The TfR is an example of a bidirectional RMT system 
that causes both the receptor-mediated transcytosis 
of holo-transferrin in the blood to brain direction, 
and the reverse transcytosis of apo-transferrin in 
the brain to blood direction. The neonatal Fc 
receptor (FcRn) is an example of a reverse RMT 
system that functions only to mediate the reverse 
transcytosis of IgG in the brain to blood direction, but not in the blood to brain direction. The type 
1 scavenger receptor (SR-VI) is an example of a receptor-mediated endocytosis system that 
mediates the uptake of modified low-density lipoprotein (LDL) from the blood compartment into 
the intraendothelial compartments, and this endocytosis is not followed by exocytosis into brain 
interstitial fluid (9). 
  
4.3.4 Drug strategies using endogenous BBB transport 
In drug industry, scientist may alter the structure of a lead molecule to increase CMT affinity. For 
example, L-Dopa is a form of dopamine, and gabapentin is a form of gaba, and both drugs are 
effective drugs because their affinity to CMT in the BBB has been enhanced thanks to structure-
activity relationships (SAR). Cloning and expression of a BBB AET by a drug developer it can be 
used to isolate “co-drugs” by High Throughput Screening (HTS). A co-drug inhibits a BBB AET 
Figure 7. Types of RMT systems. (9) 
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system, and thereby increases brain permeation of a pharmacologically active molecule that has 
limited brain penetration, owing to its export form brain via the BBB AET systems (9). 
The delivery of large molecule drugs to the brain via the BBB RMT systems requires the use of 
molecules that can ferry them across. Receptor-specific ligands or peptidomimetic monoclonal 
antibodies (MAb) can cross the BBB on an RMT system. Such molecules may act as a molecular 
Trojan horse, and ferry across the BBB a large molecule, such as a recombinant protein, a 
therapeutic MAb, an antisense agent, a non-viral plasmid DNA therapeutic, or an RNA interference 
(RNAi) drug (9). 
 
4.3.5 Receptor-mediated transcytosis 
It is also known as the molecular Trojan horse approach (1). A BBB molecular Trojan horse, as said 
above, is an endogenous peptide or peptidomimetic monoclonal antibody (MAb) that crosses the 
BBB via RMT on one of several endogenous BBB receptors. Transcytosis, means to be endocytosed 
and exocytosed, thus crossing the BBB. But not all RMT, as described in the anterior chapter, 
enable transcytosis. The most useful transporters are TfR and IR (11). 
For this reason, receptor-mediated transcytosis follows a three-step mechanism. First, the 
receptor-ligand complex is endocytosed at the luminal (blood) side. Second, the complex moves 
through the endothelia cytoplasm and third, there is the exocytosis at the abluminal (brain) side 
(4).  
  
4.3.5.1 Insulin receptor 
Insulin is a neuromodulator substance in the central 
nervous system (7). Insulin is not made in the brain and 
brain insulin arises from blood via transport across the 
BBB on the endothelial IR (10). There are also IRs widely 
distributed throughout the brain and insulin 
Figure 8. Model for insulin receptor-mediated 
transcytosis through the BBB. ISF =interstitial fluid (7). 
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concentrations are readily measurable in the brain (7). Figure 8 shows how insulin can cross the 
BBB via receptor-mediated transcytosis. 
The use of insulin as a Trojan horse could lead to hypoglycemia. Therefore, a peptidomimetic MAb 
against the human insulin receptor (HIR), HIRMAb, has been used (11).  
 
4.3.5.2 Transferrin receptor 
Brain iron originates from transferrin (Tf) in blood, which is transported into brain on the BBB TfR 
(10). There is evidence that the TfR is expressed at both luminal and abluminal membranes of the 
brain capillary endothelium (7). The RMT of Tf through the BBB follows a bidirectional system. The 
holo-transferrin (iron-bound Tf) is transcytosed from blood to brain and then endocytosed into 
brain cells, once within brain cells, Tf-Fe complex dissociates wherein brain cell ferritin can absorb 
the iron. Finally the apo-transferrin (iron-free Tf) is then transcytosed back to blood (7). 
The use of Tf as a Trojan horse is problematic, because the BBB TfR binding site for Tf is completely 
saturated by the endogenous Tf in plasma. Therefore, various species-specific MAb have been 
engineered (11). This antibodies bind to an epitope of the TfR that is different to the transferrin 
binding site (4). 
 
4.3.5.3 Properties of BBB molecular Trojan horses 
The characteristics of BBB molecular Trojan horses must enable the targeting of drugs to brain in 
pharmacologically active amounts. First, the Trojan horse must target a BBB receptor that is a 
trancytosis, not an endocytosis, system. IR and the TfR are the most used ones. Second, the Trojan 
horse should bind the BBB receptor with high affinity. Third, the high affinity binding of the 
molecular Trojan horse to the receptor must be retained following fusion or conjugation of the 
drug to the Trojan horse. Fourth, high activity of the drug must be retained following fusion or 
conjugation of the drug to the Trojan horse. Fifth, the brain uptake of the Trojan horse-drug 
molecule must be high. Sixth, in vivo CNS pharmacologic effects should be demonstrable following 
intravenous administration. The best assay of Trojan horse efficacy is an in vivo model, wherein in 
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vivo pharmacologic effects in brain are demonstrated following the intravenous administration 
(11). 
The most potent molecular Trojan horses are MAbs against mouse or rat TfR and the human HIR. 
Other ligands have been tested, but they demonstrate limitations in terms of specificity and/or 
global distribution of the transgene (12). For drug delivery in humans, genetically engineered 
forms of the HIRMAb have been produced, including a chimeric HIRMAb and a humanized HIRMAb 
(11).    
          Table 1. Species-specific peptidomimetic monoclonal antibodies for receptor-mediated transport of drugs across the BBB. (8) 
Species to be targeted Peptidomimetic monoclonal antibodies 
Mouse 8D3 rat mAb to mouse transferrin receptor (TfR) 
Rat OX26 murine mAb to rat TfR 
Rhesus monkey 83-14 murine mAb to human insulin receptor 
Human Genetically engineered chimeric mAb to human 
insulin receptor (HIR) 
 
 
4.4 DELIVERY OF DRUGS TO THE BRAIN THROUGH RMT 
There are three major technologies for delivery of drugs to the brain through RMT, and these are 
shown in figure 9 (8):  
 
Figure 9. Technologies for delivery of drugs through 
RMT. (a) Avidin (streptavidin)-biotin technology. (b) 
Fusion protein technology. (c) Trojan horse liposomes 
(THLs). SA, streptavidin; Bi, biotin; R, receptor. (8) 
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4.4.1 Avidin (streptavidin)-biotin technology  
Oligopeptides, antisense RNA, or siRNa can be delivered with avidin (streptavidin)-biotin 
technology (8). 
In this approach, a conjugate of the transport vector and avidin or neutral forms of avidin, such as 
neutral light avidin (NLA) or streptavidin (SA), are prepared in parallel with monobiotinylation of 
the drug. Owing to multivalancy of avidin or SA binding of biotin, a drug that had higher degrees of 
biotinylation than the monobiotinylated form would form high molecular weight aggregates upon 
binding to the vector/avidin or vector/SA conjugate, and would be removed rapidly from blood 
(7). This is a “2 vial” approach, where the biotinylated drug is prepared in one vial, and the 
MAb/SA is prepared in the second vial. The two vials are mixed just prior to administration, 
resulting in rapid formation of the drug-biotin/SA-MAb conjugate (13). 
Avidin is a protein which is glycosylated and has a highly cationic charge. Although avidin is a 
protein found only in birds and is not produced in humans, studies have shown that avidin or SA 
do not cause immunogenic consequences.  Avidin has a rapid plasma clearance. Given the fact of 
its rapid removal, it would be anticipated that a conjugate of a BBB-targeting vector and avidin 
would also be rapidly removed from plasma. In order to optimize the plasma pharmacokinetics, 
subsequent studies employed conjugates of the peptidomimetic MAb and neutral forms of avidin 
such as NLA or SA, and showed identical rates to that observed with transferrin (13). 
Furthermore, the genetic engineering of fusion genes of avidin or SA and BBB drug-targeting 
vectors also decreases the plasma clearance (13). 
 
4.4.2 Fusion protein technology 
Recombinant growth factors and monoclonal antibodies can be delivered with fusion protein 
technology (14).  Fusion or chimeric proteins are created through the joining of two or more genes 
which originally coded for separate proteins. Translation of this fusion gene results in a single 
polypeptide with functional properties derived from each of the original proteins (14). 
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Recombinant protein neurotherapeutics can be delivered across the BBB following the genetic 
engineering, expression and purification of recombinant fusion proteins. The neurotrophin-
antibody fusion protein is an example. Neurotrophin is a therapeutic protein that cannot be 
transported. In this approach, neurotrophin is fused to the carboxyl or amino terminus of either 
the heavy or the light chains of the genetically engineered human insulin receptor monoclonal 
antibody (HIRMAb). A fusion protein of the chimeric HIRMAb and a neuroprotective neurotrophin 
is genetically engineered, expressed and shown to retain the bifunctional properties of the fusion 
protein. The fusion protein can bind both the HIR with high affinity to enable transport across the 
BBB and then the neurotrophin receptor on brain cells, to induce neuroprotection (15).  
MAb-based therapeutics may also be delivered across the BBB with fusion protein technology. An 
example, as seen in figure 10, is the genetic engineering, expression, and validation of a fusion 
protein of the chimeric HIRMAb and a single chain Fv (ScFv) 
antibody to the Aβ amyloid peptide of Alzheimer’s disease 
(AD). Anti-Aβ antibodies are potential therapeutics of AD, as 
these agents disaggregate the amyloid plaque of AD following 
the intra-cerebral injection of the anti-Aβ antibody. The aim of 
either active or passive immunization therapy of AD is to use 
MAb-based therapeutics to deplete the brain of Aβ amyloid 
plaque. However, in the case of either active or passive 
immune therapy of AD, it is necessary for the anti-Aβ MAb to 
cross the BBB in both the blood to brain and brain to blood 
directions. There is no IgG transporter at the BBB to mediate the blood to brain transport of these 
large molecules. Therefore, IgG therapeutics do not cross the BBB in the blood to brain direction, 
since these molecules lack affinity for any BBB receptor/transporter. However, MAb-therapeutics 
can be made to cross the BBB via RMT following the re-engineering of these molecules as fusion 
proteins with a BBB molecular Trojan horse. The structure of a genetically engineered fusion 
antibody of the HIRMAb and the anti-Aβ ScFv is shown in figure 10. This fusion antibody is a tri-
functional molecule that is comprised of three domains. The first domain is the HIRMAb at the 
head of the molecule, which mediates the RMT of the fusion antibody from blood to brain across 
the BBB via the endogenous BBB HIR. The second domain is the anti-Aβ ScFv at the tail of the 
Figure 10. Structure of a genetically engineered 
fusion protein of the chimeric HIRMAb and a single 
chain Fv (ScFv) antibody to the Aβ amyloid peptide 
(15). 
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fusion antibody, which allows binding to and disaggregation of Aβ amyloid plaque within the brain 
behind the BBB. The third domain is the CH2-CH3 interface in the midsection of the molecule, 
which is the binding site for the BBB FcRn. The BBB FcRn mediates the efflux of the fusion antibody 
in the brain to blood direction via reverse transcytosis across the BBB in vivo. All three 
functionalities of the fusion antibody are retained following genetic engineering and expression of 
this molecule. The intra-cerebral injection of the fusion antibody into double transgenic AD mouse 
brain results in a 40% clearance of Aβ amyloid plaque within 48h (15). 
 
4.4.3 Trojan horse liposomes (THLs technology) 
Non-viral plasmid DNAs or genes encoding shRNAs are examples of large molecules that may be 
shuttled to the brain with THLs. This technique will be explained in detail in the following chapters. 
 
4.5 GENE THERAPY OF THE CENTRAL NERVOUS SYSTEM 
Nowadays just few brain disorders can be treated effectively, and these include affective 
disorders, chronic pain, epilepsy and migraine headache. Parkinson’s disease (PD) patients are 
given L-DOPA for dopamine replacement therapy. L-DOPA is an example of a BBB drug targeting 
strategy. However, there is no treatment that stops the neurodegeneration of PD. The same 
happens with other neurodegenerative diseases such as AD, Huntington’s disease, and amytrophic 
lateral sclerosis. In the case of multiple sclerosis, the actual therapy does not permanently stop the 
progression. The human immunodeficiency virus infects the brain early in the course of acquired 
immune deficiency syndrome and the highly active antiretroviral therapy (HAART) which is 
effective in the periphery, does not access completely into the brain due to the efflux transport of 
some HAART drugs. Other serious brain disorders such as brain cancer or stroke lack effective drug 
therapy (9).  
Many of these brain diseases are due to genetic mutations. Some examples include Huntington’s 
disease, familial AD or amyotrophic lateral sclerosis. For this reason, gene therapy is an approach 
that seems to fulfill the need of an effective treatment. However, the development of genes as 
drugs brings into focus the need to discover new techniques to target genes across the BBB. To 
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develop new strategies, a thorough understanding of the BBB structure and functions is primordial 
(7).  
The most widely applied method of brain gene delivery is craniotomy, with the intracerebral 
introduction of therapeutic genes formulated in either viruses or cationic liposomes. In parallel 
with the craniotomy-based methods of drugs or gene delivery to the brain, there is a line of 
investigation aimed at disrupting the BBB. Both, disrupting the BBB and craniotomy, are invasive 
procedures and may induce chronic neuropathologic effects in brain (7). 
Another approach is the noninvasive administration of gene medicines to the brain via BBB 
endogenous transport systems. This approach has two advantages (7). First, a global distribution 
of the transgene throughout the brain (16). In contrast, when gene medicines are delivered by 
craniotomy approaches, the treatment volume is reduced due to the limitations of diffusion within 
the brain. The second advantage is that the gene formulation can be given by an intravenous or 
subcutaneous route of administration that is no more invasive than that used by insulin-
dependent patients. The formulations of gene medicines that are used in present practice are 
based on viruses, cationic liposomes, or naked DNA/polylysine conjugates (7). Viruses have been 
used as brain DNA delivery systems with disappointing results associated with preexisting 
immunity, immunological response induced by viral coat proteins, and inflammation that led to 
demyelination. Therefore, nonviral approaches, such as cationic liposomes, appeared (16). In this 
approach, cationic lipids form complexes with DNA (7). Cationic liposomes are widely used for 
transfection of DNA in vitro. However, cationic lipid-DNA complexes in vivo are unstable or form 
large molecular weight aggregates that deposit in the pulmonary vascular bed, which decreases its 
bioavailability (16). On the other hand, naked DNA/polylysine conjugates are a result of the 
conjugation between a receptor ligand and a polylysine, using approaches that include either 
chemical linkages or avidin-biotin technology. The polycationic polylysine then binds to the 
polyanionic DNA and goes through a receptor-mediated transport. However, although it proves to 
be effective in cell cultures, it is apparently less effective in vivo (7). 
An alternative is the THL technology that will be explained in the next chapter.  
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4.6 TROJAN HORSE LIPOSOMES 
THLs are pegylated liposomes containing a supercoiled plasmid DNA molecule or genes encoding 
shRNAs in the interior of the liposome (16). Therefore, it is an appropriate technique for gene 
therapy.  
4.6.1 Structure of a Trojan horse liposome (THL) 
 
 
 
 
 
 
 
Figure 11 shows the structure of a THL encapsulating a plasmid DNA. A supercoiled plasmid DNA is 
encapsulated in the interior of the THL. The plasmid encodes for a coding sequence, the 
expression of which is under influence of a promoter, and a polyadenylation sequence. The 
promoter eliminates ectopic transgene expression and enables the expression in targeted regions 
of the CNS (16). The encapsulation of DNA and sizing of the THL are completed by forced extrusion 
through a series of polycarbonate filters of reduced pore size to form liposomes of 80-100 nm 
diameter. The DNA in excess, i.e. either free DNA or DNA bound to the exterior of the liposome, is 
removed from the preparation by digestion with a mixture of DNA endonuclease I and 
exonuclease II to avoid interference with the conjugation to the target MAb (17). 
In order to achieve maximum targeting, liposomes should remain in the systemic circulation for a 
relatively long time, although several formulations of liposomes used in the past were rapidly 
removed from the circulation by the reticuloendothelial system (RES). Furthermore, it is known 
that coating liposomes with antibodies leads to enhanced uptake of the immunoliposomes by the 
RES. Liposomes containing amphipathic polyethylene glycol (PEG) derivatives are not readily taken 
Figure 11. Engineering of a Trojan horse liposome. A 
supercoiled plasmid DNA is encapsulated in the interior of the 
THL. The plasmid encodes for a coding sequence (cds), the 
expression of which is under the influence of a promoter 
(pro), that is, SV40, and a polyadenylation sequence (pA). The 
surface of the liposome contains a lot of strands of 
polyethylene glycol (PEG) to stabilize the complex in blood. 
About 1-2% of these strands are conjugated with MAbs, which 
trigger transport (16).  
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by the macrophages in the RES. PEG is useful because of its easy preparation, low cost, 
controllability of molecular weight and linkability to lipids or proteins including antibodies. For this 
reason, the surface of the liposome contains thousands of strands of polyethylene glycol (PEG) 
which stabilize the complex in blood.  Approximately 1-2% of the PEG strands are conjugated with 
a MAb, which triggers transport of the THL across barriers in vivo. MAbs are almost always species 
specific, thus THLs are engineered with one or different type of MAb to target both the BBB and 
brain cells, depending on the origin of the receptor (animal or human) or in case the receptors in 
both barriers are different. The targeted receptor must be present in both BBB and brain cell 
membranes to transport drugs into the brain cells. IR and TfR are highly expressed in both barriers, 
and so MAbs against these two receptors enable the sequential receptor-mediated transcytosis of 
the THL across the BBB followed by the receptor-mediated endocytosis of the THL into the brain 
cells (12). 
THLs are engineered with a mixture of naturally occurring lipids that has been optimized for the 
encapsulation of the plasmid DNA (12).  
Liposomes are comprised of 93% of 1-palmitoyl-2-oleoyl-sn-glycerol-3-phospocholine (POPC), 3% 
of didodecyldimethylammonium bromide (DDAB), 3% of distearoylphosphatidylethanolamine 
(DSPE)-PEG2000, and 1% of DSPE-PEG2000-maleimide. The maleimide functional group allows for 
covalent conjugation of a thiolated MAb via a stable thioether linkage (12). 
Plasmid DNA-based gene therapy with THL technology involves episomal gene expression and 
must be given on a chronic basis, which arises concerns about potential toxic side effects from 
repeated dosing. However, toxicity studies have shown that there is no toxicity as a result of 
chronic dosing (12). 
Formulation optimization can enhance the efficacy of this technique as for example the recent use 
of ethanol-mediated DNA condensation to increase the efficiency of DNA encapsulation (18). 
Avidin-biotin technology may also facilitate conjugation of ligands to THLs (19). 
Another application suitable for the THL technology is RNA interference (RNAi), which represents 
one of the most potent mechanisms of gene downregulation. RNAi has been extensively 
demonstrated in cell culture by lipofection with RNA duplexes. However, the delivery of short RNA 
fragments into cells in vivo in mammals is problematic owing to the rapid degradation of the RNA. 
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Short hairpin RNA (shRNA) mimics the structure of the RNAi duplex, and shRNA can be produced 
in cells following the delivery of expression plasmids encoding the shRNA. This shRNA is then 
processed in the cell by the enzyme dicer to form an RNA duplex with a 3’-overhang and this short 
RNA duplex mediates RNAi or post-transcriptional gene silencing. RNAi activity has been shown in 
cell culture by transfecting cells with plasmids producing shRNAs, using gene delivery systems 
comprised of either cationic polyplexes or retroviral vectors. However, as it has been said above, 
cationic DNA polyplexes (i.e. lipofection) or retroviral vectors do not cross the BBB (17).  
RNAi-based gene therapy offers promise for the treatment of cancer and other brain disorders like 
AD. Recent studies demonstrated its efficacy directed at the human epidermal growth factor 
(EGFR) in an experimental human brain tumor model in mice (17). 
In this case THLs may be engineered with shRNA expression vectors driven by the U6 promoter 
and encoding a T5 terminator sequence for RNA polymerase III after the 3’-end of the shRNA (17). 
 
4.6.2 Important aspects of THL design 
There are three important aspects in the design of the THL that may substantially affect the levels 
and specificity of the expression of the exogenous gene to be delivered (17): 
1) Targeting ligand: the targeting ligand represents an important factor in determining the 
levels of expression of the exogene to be delivered with the THL. Studies then show that IR 
represents the preferred pathway for delivery of transgenes to cells with this technology. 
2) Introduction of regulatory sequences in the plasmid DNA: cis-regulatory sequences are 
important regulatory elements that modulate the expression of transcripts. These 
sequences are short (~200bp) and do not affect the final nucleotide load to THLs. 
3) Use of tissue specific promoters in the plasmid DNA: these promoters prevent ectopic 
expression and allow brain cell-specific expression of the transgene of interest in vivo in 
animal studies. 
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4.6.3 Technique validation 
The THL plasmid DNA gene transfer technology has been validated in multiple animal models in 
mice, rats, and Rhesus monkeys, and so it is possible to deliver transgenes to brain. The ectopic 
expression of the transgene can be eliminated by the combined use of THLs and plasmid DNA 
engineered with tissue-specific gene promoters. Transgene expression is shown to be reversible 
because the plasmid DNA is not integrated into the host genome and this property is 
advantageous, since the integration of viral genomes into the host DNA can lead to mutagenesis. 
An increase in the duration of plasmid DNA expression is possible with the incorporation of 
chromosomal elements to the plasmid DNA. THLs can also be administered chronically without 
toxicity or immune reactions (16).  
 
4.7 RESEARCH AND FUTURE PERSPECTIVES 
In vivo applications of THLs were initially investigated with luciferase and lacZ reporter genes. THLs 
were constructed with the expression plasmid of the luciferase reporter gene, and engineered 
with either the TfRMAb for rodents or the HIRMAb for Rhesus monkeys (16). Tissue-specific gene 
expression with the combined use of THLs and the opsin promoter was also demonstrated in vivo 
in the Rhesus monkey (20). In vivo efficacy of THLs has been investigated in a model of 
mucopolysaccharidosis (MPS), a lysosomal storage disorder that affects the CNS. The non-viral 
plasmid DNA encoded a lysosomal enzyme, β-glucuronidase (GUSB). After intravenous Trojan 
horse liposome administration there was an increase of brain GUSB enzyme activity (21). The 
therapeutic efficacy of THLs has been also demonstrated in vivo in a model of PD (22). PD is 
associated with a loss of dopaminergic neurons in the substantia nigra and the rate limiting 
enzyme in the synthesis of dopamine is tyrosine hydroxylase (TH), thus, a potential treatment for 
PD is TH gene replacement therapy. In that study, pegylated immunoliposomes (PIL) nonviral gene 
transfer technology enabled normalization of striatal tyrosine hydroxylase activity. On the other 
hand, plasmid DNA that produces short hairpin RNA for the purposes of silencing genes via 
pegylated immune liposome (PIL) gene targeting technology in brain cancer was first studied with 
the luciferase gene as the target and the result showed an effective gene therapy delivery. 
Following these results, the ability of knocking down the EGFR which is expressed in 90% of 
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primary brain cancers, was evaluated. This resulted in an increase in survival time in adult mice 
(23). 
A lot of research has been done using the avidin-biotin approach. Table 2 summarizes in vivo CNS 
pharmacologic effects in brain following intravenous administration of large molecule drugs using 
this technique (11). 
For drug delivery in humans, genetically engineered forms of the HIRMAb have been produced, 
including a chimeric HIRMAb and a humanized HIRMAb. Innovation in brain drug development is 
now focused on the engineering of bifunctional fusion proteins of a BBB Trojan horse and the 
therapeutic protein. To date, HIRMAb fusion proteins have been engineered for multiple types of 
biopharmaceuticals as shown in Table 3 (24). Table 4 shows recent in vivo pharmacological effects 
in the brain following the administration of Trojan horse fusion proteins (24).   
The future step is to translate these technologies to humans with the use of human-specific 
antibodies that are genetically engineered to reduce immunogenicity such as the chimeric and 
humanized HIRMAb (16). Finally, it is worth adding a comment about a recent in vivo study which 
opens a debate in whether monoclonal antibodies targeting the TfR undergo receptor-mediated 
transcytosis into the brain. Researchers argued that many studies assume this transcytosis with 
the use of indirect outcome measures such as protein expression or enzymatic activity. Studies 
that examined direct evidence by using radiolabelling and immunohistochemical approaches 
concluded that there was transport into the endothelial cells but not exocytosis into the brain (25). 
Nevertheless, studies performed about delivery of drugs through Trojan horse liposomes and 
other strategies directed to avoid BBB are of relevant importance for the treatment of CNS 
disorders. 
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Table 2 In vivo CNS pharmacologic effects in brain following intravenous administration of large molecule drugs 
using the avidin-biotin technique.  
Drug In vivo CNs pharmacological effect Reference 
VIP Increase in cerebral blood flow (26) 
BDNF Complete neuroprotection of hippocampal CA1 neurons in 
translent forebrain ischemia 
(27) 
BDNF 65-70% reduction in stroke volume in permanent or reversible 
middle cerebral artery occlusion 
(28, 29) 
FGF-2 80% reduction in stroke volume in permanent middle cerebral 
artery occlusion 
(30) 
Aβ1-40 Imaging brain amyloid in vivo with peptide radiopharmaceutical (31) 
EGF Early detection of brain cancer in vivo with peptide 
radiopharmaceutical 
(32) 
PNA Imaging gene expression in vivo with antisense 
radiopharmaceutical 
(33) 
VIP, vasoactive intestinal peptide; BDNF, brain-derived neurotrophic factor; FGF, fibroblast growth factor; EGF, epidermal 
growth factor; PNA, peptide nucleic acid.  
 
 
Table 3 IgG Fusion proteins engineered for targeted brain delivery 
Category Protein therapeutic Reference 
Neurotrophins BDNF 
GDNF 
Erythropoietin (EPO) 
(34) 
(35) 
(36) 
Enzyme IDUA 
IDS 
GUSB 
Paraoxonase (PON)-1 
(37) 
(38) 
(39) 
(40) 
Decoy receptor Tumor necrosis factor receptor (TNFR) 
type II 
(41) 
Monoclonal antibody Antiamyloid antibody (AAA) (42) 
Other Avidin (43) 
BDNF, brain-derived neurotrophic factor; GDNF, glial-derived neurotrophic factor; IDUA, α-L-Iduronidase; IDS, Iduronate-
2-sulfatase 
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Table 4 In vivo pharmacological effects in the brain following the administration of Trojan horse fusion proteins 
Species Route Drug Disease Reference 
Rat Intracranial EPO Stroke (44) 
Mouse Intravenous 
Intravenous 
Intravenous 
Intravenous 
Intravenous 
EPO 
EPO 
GDNF 
AAA 
IDUA 
Stroke 
Parkinson’s disease 
Parkinson’s disease 
Alzheimer’s disease 
Hurler’s syndrome 
(45) 
(46) 
(47) 
(48) 
(49) 
EPO, erythropoietin; GDNF, glial-derived neurotrophic factor; AAA, antiamyloid antibody; IDUA, α-L-Iduronidase 
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5. CONCLUSIONS 
• The BBB is formed by endothelial cells, pericytes, astrocytes and a basement membrane 
and these components are responsible for its particular properties.  
• Endothelial cells from brain capillaries have specific features that help to maintain a 
restrictive permeability.  
• Endothelial cells and pericytes share a common basement membrane which controls 
movement of charge solutes and serves as a repository of growth factors.  
• Astrocytes are comprised of various foot processes that can contact different structures 
and this property makes them capable of maintaining the optimum neuronal environment. 
• The BBB has a restricted transport. The paracellular pathway is limited by tight junctions 
and only small lipid soluble substances can pass by passive diffusion. The rest of molecules, 
even if they are essential, need an specific transporter.  
• The presence of efflux transporters in the BBB makes the transport of its substrates even 
more difficult. This protective property is a disadvantage for most drugs.  
• Other types of transports across the BBB are the carrier-mediated transport, adsorptive-
transcytosis, receptor-mediated transcytosis and cell-mediated transcytosis. 
• Carrier-mediated transporters serve mainly to transport nutrients into the central nervous 
system and RMT include the insulin or TfRs which enable transcytosis of its respective 
substrates into the brain, transcytosis from the brain into blood and endocytosis into 
endothelial cells.  
• Some drug strategies may be used to enhance transport across the BBB such as modifying 
the structure of a drug to act as a substrate of a carrier-mediated transporter, inhibiting 
active efflux system or using receptor-specific ligands or MAbs, as molecular Trojan horses, 
to ferry drugs into the brain via receptor-mediated transcytosis.  
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• A useful molecular Trojan horse needs to achieve certain necessary properties and for this 
reason the most used ones are MAbs. 
• Avidin(streptavidin)-biotin, fusion protein and Trojan horse liposomes are three different 
technologies used to deliver drugs through receptor-mediated transcytosis. As gene 
therapy becomes a new approach to treat many brain diseases, the Trojan horse liposome 
technique seems to have advantages to other formulations used in present practice. 
• A Trojan horse liposome is comprised of three principal elements. First, a liposome which 
can encapsulate both plasmid DNA or shRNA. Second, PEG which stabilize the complex in 
blood and third, a MAb which enables the binding to an specific receptor. Besides, the 
construction of a THL has been optimized to enhance its efficacy and the technique has 
been validated in multiple animal models. 
• In vivo efficacy of THL has been demonstrated in many animal studies and in various 
disease models and the same happens with the avidin(streptavidin)-biotin technology.  
• Innovation in drug development is focused on the fusion protein technique. To date, 
HIRMAb fusion proteins have been engineered for multiple classes of biopharmaceuticals. 
• Most of the research that has been done seems to indicate that these techniques can be 
useful to treat CNS disorders. 
• A future step would be reaching clinical trials using chimeric o humanized MAbs, which 
could be useful in crossing the human BBB. 
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